drugset / Trial / NCT06409650
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.
Timeline
- Start
- 2021-11-09
- Primary completion
- 2022-11-10
- Completion
- 2023-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KX-826 | Unknown | 2.5 mg | Topical |
| Subject | KX-826 | Unknown | 5 mg | Topical |